News and Press Releases
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of 8.9...
Category: Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Enterprise Therapeutics appoints Dr Renu Gupta as chief medical officer and Dr Janet Hammond as non-executive director
Appointments bring additional respiratory and late clinical-stage drug development experience as company commences Phase 2a clinical trial of its lead asset 17 June 2024, Brighton, UK -: Enterprise Therapeutics Ltd...
Category: Biotechnology, Pharmaceutical
Posted: June 17, 2024
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
TALVEY (talquetamab) demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
24-month overall survival rate of 67% achieved with talquetamab 0.8mg/kg biweekly dosing in the phase 1/2 MonumenTAL-1 study 14 June 2024 – Beerse, Belgium – Janssen-Cilag International NV, a Johnson...
Category: Biotechnology, Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Updated phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
At 5 years, 67% of patients were progression-free, with overall survival at 96% for all treated patients 14 June 2024 – Beerse, Belgium – (GLOBE NEWSWIRE) – Janssen-Cilag International NV,...
Category: Biotechnology, Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
CluePoints Continues ‘Turning Artificial Intelligence into Human Intelligence’ by Launching Two New Innovations
Site Profile & Oversight Tool (SPOT) and Intelligent Medical Coding (IMC) unveiled by RBQM innovator at DIA Global Annual Meeting 2024 17 June 2024 -- Pennsylvania, US -- CluePoints, provider...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: June 17, 2024
Thermo Fisher Scientific Showcases Clinical Research Innovation at DIA Annual Meeting
PPD clinical research business leads real-world data and technology panel, receives CRO Leadership Award 17 June 2024 -- California, US -- The PPD clinical research business of Thermo Fisher Scientific,...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 17, 2024
Transatlantic accolade for Tower Cold Chain’s investment into US
11 June 2024 – Temperature-controlled container specialist Tower Cold Chain has received a prestigious Transatlantic Growth Award (TAG) for its investment into North America. The TAGs are awarded by BritishAmerican...
Category: Manufacturing and Packing
Posted: June 14, 2024
Unit A, Total Park, Station Road, Theale, Reading, Berkshire RG7 4PN, UK
Sphere Fluidics awarded Gold accreditation by Investors in People
Internationally-recognized ‘We invest in people’ award is certified recognition of the Company’s care and commitment to its employees globally 14 June, 2024 - Cambridge, UK - Sphere Fluidics, a leading...
Category: Biotechnology, Drug Discovery
Posted: June 14, 2024
The Jonas Webb Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdom
China’s Innovent holds potential to change pancreatic cancer treatment landscape with bispecific antibody IBI389, says GlobalData
14 June 2024 - China-based Innovent Biologics recently presented phase 1 study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer at the 2024...
Category: Biotechnology, Pharmaceutical
Posted: June 14, 2024
New Kite Clinical Research and Real-World Evidence for Yescarta (Axicabtagene ciloleucel) Demonstrate Benefit From Earlier Lines of Treatment
Analysis shows manufacturing of axicabtagene ciloleucel in second-line treatment of relapsed/refractory large B-cell lymphoma can help reduce time from leukaepheresis to infusion vs third-line plus treatment Data builds on previous...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 14, 2024
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and...
Category: BioManufacturing, Biotechnology, Pharmaceutical
Posted: June 14, 2024
Tapinarof may mark Dermavant’s first atopic dermatitis approval, says GlobalData
Dermavant's VTAMA (tapinarof), a nonsteroidal, topical AhR-modulating agent, achieved positive phase 3 trial results in atopic dermatitis patients aged two and above, leading to Food and Drug Administration (FDA) acceptance...
Category: Drug Discovery, Pharmaceutical
Posted: June 13, 2024
Formycon reports on the results of the annual general meeting
Management provides detailed report on financial year 2023 and current company performance. Shareholders approve all agenda items and formally approve the acts of the members of the management board and...
Category: BioManufacturing
Posted: June 13, 2024
Deep Genomics Expands Executive Leadership and Operations in Latest Strategic Growth Initiative
Company announces executive new hires and marks significant momentum with Cambridge, Massachusetts, US, site opening and Toronto, Canada, office expansion 13 June 2024 -- Massachusetts, US -- Deep Genomics, the...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 13, 2024
480 University Ave, Suite 1300 Toronto, Ontario, Canada, M5G 1V2
Terminally sterilised plastic bottled media range launched to support sustainability initiatives
Cherwell’s new Redipor Plastic Bottle media range provides more sustainable alternative to glass bottled media for sterile pharmaceutical manufacturing 13 June 2024 -- Bicester, UK -- Cherwell, cleanroom microbiology solutions...
Category: Manufacturing and Packing, Other
Posted: June 13, 2024
Launton Business Centre Murdock Rd, Bicester OX26 4XB
